Across TCGA pan-cancer cohorts, PGAP1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PGAP1 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PGAP1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PGAP1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, HNSC, and UCEC are the cancer types where PGAP1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.097	0.549	<.001	22	view →
HNSC	OS	Median	III,IV	0.163	0.680	.001	12	view →
UCEC	DFS	Median	All	0.925	0.620	.014	10	view →
LGG	DFS	Median	All	0.463	0.740	.028	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PGAP1 tumor-vs-normal RNA expression · all PGAP1 data types